Ubs Group Ag Kymera Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 557,734 shares of KYMR stock, worth $31.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

557,734

Previous 593,606 6.04%

Holding current value

$31.4 Million

Previous $16.2 Million 49.82%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$21.05 - $48.6 $755,105 - $1.74 Million	-35,872 Reduced 6.04%	557,734 $24.3 Million
Q1 2025 May 13, 2025	BUY	$27.37 - $44.36 $3.39 Million - $5.49 Million	123,764 Added 26.34%	593,606 $16.2 Million
Q4 2024 Feb 14, 2025	BUY	$39.06 - $51.84 $9.85 Million - $13.1 Million	252,223 Added 115.9%	469,842 $18.9 Million
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $220,710 - $383,463	7,318 Added 3.48%	217,619 $10.3 Million
Q2 2024 Aug 13, 2024	SELL	$29.85 - $39.42 $2.58 Million - $3.41 Million	-86,379 Reduced 29.12%	210,301 $6.28 Million
Q1 2024 May 13, 2024	SELL	$22.9 - $43.57 $86,630 - $164,825	-3,783 Reduced 1.26%	296,680 $11.9 Million
Q4 2023 Feb 09, 2024	BUY	$10.97 - $26.84 $1.51 Million - $3.7 Million	137,704 Added 84.61%	300,463 $7.65 Million
Q3 2023 Nov 09, 2023	SELL	$13.9 - $23.88 $1.08 Million - $1.86 Million	-77,957 Reduced 32.39%	162,759 $2.26 Million
Q2 2023 Aug 11, 2023	BUY	$22.4 - $34.92 $1.24 Million - $1.94 Million	55,421 Added 29.91%	240,716 $5.53 Million
Q1 2023 May 12, 2023	SELL	$24.84 - $38.75 $433,855 - $676,807	-17,466 Reduced 8.61%	185,295 $5.49 Million
Q4 2022 Feb 08, 2023	BUY	$19.57 - $30.92 $3 Million - $4.73 Million	153,076 Added 308.09%	202,761 $5.06 Million
Q3 2022 Nov 10, 2022	SELL	$20.91 - $34.27 $1.29 Million - $2.12 Million	-61,784 Reduced 55.43%	49,685 $1.08 Million
Q2 2022 Aug 10, 2022	SELL	$14.13 - $42.55 $347,894 - $1.05 Million	-24,621 Reduced 18.09%	111,469 $2.19 Million
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $2.36 Million - $4.33 Million	66,974 Added 96.9%	136,090 $5.76 Million
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $2.79 Million - $3.66 Million	55,873 Added 421.91%	69,116 $4.39 Million
Q3 2021 Nov 15, 2021	SELL	$47.8 - $66.66 $635,596 - $886,378	-13,297 Reduced 50.1%	13,243 $778,000
Q2 2021 Aug 13, 2021	BUY	$31.08 - $51.95 $34,125 - $57,041	1,098 Added 4.32%	26,540 $1.29 Million
Q1 2021 May 12, 2021	BUY	$35.64 - $85.46 $777,985 - $1.87 Million	21,829 Added 604.18%	25,442 $989,000
Q4 2020 Feb 11, 2021	BUY	$28.07 - $87.83 $94,932 - $297,041	3,382 Added 1464.07%	3,613 $224,000
Q3 2020 Nov 12, 2020	BUY	$26.1 - $33.28 $6,029 - $7,687	231 New	231 $7,000

Others Institutions Holding KYMR

# of Institutions

217

Shares Held

72.2M

Call Options Held

178K

Put Options Held

64.6K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $3.08B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account